A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC

Studiedetails

Type carcinoma: NSCLC met mutatie
Stadium: III-IV
Mutatie: KRAS
Lijn: 1e
Site: ETZ
Contactgegevens:

b.debruijn@etz.nl; ETZ_NL_lung_trial@etz.nl
Website:

 Inclusiecriteria

In order to be eligible to participate in this study, a patient must meet all of the following criteria:

– Treatment-naïve advanced or metastatic stage IIIB, IIIC or IV nonsquamous NSCLC
– KRAS G12C mutation
– PD-L1 all-comers
– ECOG PS 0 or 1

 Exclusiecriteria

A potential patient who meets any of the following criteria will be excluded from participation in this study:

– Active CNS metastases
– Interstitial lung disease

Meer studies

Een overzicht van alle lopende studies binnen het longkankernetwerk. Filter op type mutatie: